PD-1 Targeted IL-15/IL-15Ralpha Fc Fusion Proteins with Improved Properties

ChangeBridge: EPO Bulletin - Therapeutics (A61P)

Published March 25th, 2026

Detected April 1st, 2026

Summary

The European Patent Office published patent application EP4041303A1 for PD-1 targeted IL-15/IL-15Ralpha Fc fusion proteins with improved properties for cancer treatment. Co-applicants Genentech, Inc. and Xencor, Inc. filed the application covering therapeutic fusion proteins. The patent designates all EU member states.

View original document View source feed page

What changed

EPO published patent application EP4041303A1 for IL-15/IL-15Ralpha Fc fusion proteins designed for PD-1 targeted cancer treatment. The application includes 11 named inventors and covers therapeutic compositions in IPC classes A61K, A61P, and C07K. The designated states include all EU member states plus several EEA countries.

Patent publication does not create compliance obligations for generic drug manufacturers or biosimilar developers. Competitors should review the patent claims to assess freedom-to-operate for their own IL-15/IL-15Ralpha programs. The patent grants no immediate market exclusivity—enforcement and potential infringement concerns arise only upon grant and commercialization.

Source document (simplified)

← EPO Patent Bulletin

PD-1 TARGETED IL-15/IL-15RALPHA FC FUSION PROTEINS WITH IMPROVED PROPERTIES

Publication EP4041303A1 Kind: A1 Mar 25, 2026

Applicants

Genentech, Inc., Xencor, Inc.

Inventors

DESJARLAIS, John, BERNETT, Matthew, HEDVAT, Michael, VARMA, Rajat, SCHUBBERT, Suzanne, BONZON, Christine, RASHID, Rumana, DIAZ, Juan, HOLDER, Patrick, HUANG, Christine, LIU, Ke

IPC Classifications

A61K 39/395 20060101AFI20210416BHEP A61P 35/00 20060101ALI20210416BHEP C07K 14/54 20060101ALI20210416BHEP C07K 14/715 20060101ALI20210416BHEP C07K 16/08 20060101ALI20210416BHEP C07K 16/28 20060101ALI20210416BHEP A61K 39/00 20060101ALI20210416BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →